Lopinavir + ritonavir (LPV/r)
Pharmaceutical forms
Capsule
Country lists
ATC N/A
Composition 133.3 mg + 33.3 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • No observations
Bolivia
LINAME 2011 - 2013
  • No observations
Ecuador
Essential Medicines List - Ecuador
  • No observations
Chile
Essential and Prioritized Medications
  • No observations
Oral liquid
Country lists
ATC N/A
Composition 400 mg + 100 mg/5 ml
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • No observations
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • Others observations:
    Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times.
Peru
6.4.2.3 Protease Inhibitors
  • No observations
Tablet (heat stable)
Country lists
ATC N/A
Composition 100 mg + 25 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • No observations
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • Others observations:
    Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times.
Tablet (heat stable)
Country lists
ATC N/A
Composition 200 mg + 50 mg
Observations for this pharmaceutical form can be found on the lists:
WHO Model List of Essential Medicines
6.4.2.3. Protease inhibitors
  • No observations
PAHO Strategic Fund Medicine List
2.5. Antiretrovirals
  • No observations
Peru
6.4.2.3 Protease Inhibitors
  • No observations
Oral liquid
Country lists
ATC N/A
Composition 80 + 20 mg/ml
Observations for this pharmaceutical form can be found on the lists:
Chile
Essential and Prioritized Medications
  • No observations